Detail akcie Tenax Therapeut Rg online

Business Summary: Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tenax Therapeutics Inc revenues was not reported. Net loss increased from $11.3M to $37.1M. Higher net loss reflects Other Research and development increase from $7.4M to $17.7M (expense), General and administrative increase of 87% to $3.2M (expense), Personnel in R& D increase from $733K to $1.5M (expense).